Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients
The Korean Journal of Internal Medicine
;
: 15-19, 1999.
Artigo
em Inglês
| WPRIM
| ID: wpr-153282
ABSTRACT
The treatment of infectious complications in cancer patients has evolved as a consequence of the developments in the chemotherapy of cancer patients. In this prospective, randomized study, we compared imipenem-cilastatin and sulbactam-cefoperazone with amikacin in the empiric therapy of febrile neutropenic ( 0.05). No major adverse effects occurred. This study demonstrated that imipenem-cilastatin monotherapy and combination therapy of sulbactam-cefoperazone plus amikacin were equally effective empiric therapy for febrile granulocytopenic cancer patients.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Amicacina
/
Cilastatina
/
Sulbactam
/
Cefoperazona
/
Imipenem
/
Estudos Prospectivos
/
Adolescente
/
Bacteriemia
/
Quimioterapia Combinada
/
Febre
Tipo de estudo:
Ensaio Clínico Controlado
/
Estudo observacional
Limite:
Adulto
/
Idoso
/
Aged80
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
The Korean Journal of Internal Medicine
Ano de publicação:
1999
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS